The endothelial function in cardiac surgery

Research output: Contribution to journalArticle

Abstract

Cardiac operations with cardiopulmonary bypass exerts many different actions which modify the natural function of endothelial cells. The main determinant is the activation of the coagulation system both through the intrinsic and extrinsic pathways, leading to an overwhelming thrombin formation. To counteract the coagulant effects of thrombin, heparin is used in large doses. As a result, the endothelium is asked to promote all its anticoagulant properties, basically through the AT release from the suface, the tissue factor pathway inhibitor release, and the activation of the protein C - protein S system. At the end of cardiac operations, all these systems are depleted, and low levels of antithrombin, tissue factor pathway inhibitor, protein C are available for further anticoagulant effects. There is the evidence that levels of antithrombin activity below 50% at the end of cardiac operations with cardiopulmonary bypass are associated to bad outcomes in terms of surgical revision rate, thromboembolic events, and neurological events. Exogenous antithrombin administration has a well defined action in limiting thrombin formation during cardiac operations; however, we are still lacking an evidence-based information about the clinical impact of this and others possible preventive strategies based on exogenous administration of antithrombin before or during cardiac operations.

Original languageEnglish
Pages (from-to)503-506
Number of pages4
JournalMinerva Anestesiologica
Volume72
Issue number6
Publication statusPublished - Jun 2006

Fingerprint

Antithrombins
Thoracic Surgery
Thrombin
Protein C
Cardiopulmonary Bypass
Anticoagulants
Coagulants
Protein S
Reoperation
Endothelium
Heparin
Endothelial Cells
lipoprotein-associated coagulation inhibitor

Keywords

  • Cardiopulmonary bypass
  • Coagulation
  • Endothelium, vascular

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine

Cite this

The endothelial function in cardiac surgery. / Ranucci, M.

In: Minerva Anestesiologica, Vol. 72, No. 6, 06.2006, p. 503-506.

Research output: Contribution to journalArticle

@article{806a0b1ed0794bc6b7b7e4ef559c6a92,
title = "The endothelial function in cardiac surgery",
abstract = "Cardiac operations with cardiopulmonary bypass exerts many different actions which modify the natural function of endothelial cells. The main determinant is the activation of the coagulation system both through the intrinsic and extrinsic pathways, leading to an overwhelming thrombin formation. To counteract the coagulant effects of thrombin, heparin is used in large doses. As a result, the endothelium is asked to promote all its anticoagulant properties, basically through the AT release from the suface, the tissue factor pathway inhibitor release, and the activation of the protein C - protein S system. At the end of cardiac operations, all these systems are depleted, and low levels of antithrombin, tissue factor pathway inhibitor, protein C are available for further anticoagulant effects. There is the evidence that levels of antithrombin activity below 50{\%} at the end of cardiac operations with cardiopulmonary bypass are associated to bad outcomes in terms of surgical revision rate, thromboembolic events, and neurological events. Exogenous antithrombin administration has a well defined action in limiting thrombin formation during cardiac operations; however, we are still lacking an evidence-based information about the clinical impact of this and others possible preventive strategies based on exogenous administration of antithrombin before or during cardiac operations.",
keywords = "Cardiopulmonary bypass, Coagulation, Endothelium, vascular",
author = "M. Ranucci",
year = "2006",
month = "6",
language = "English",
volume = "72",
pages = "503--506",
journal = "Minerva Anestesiologica",
issn = "0375-9393",
publisher = "Edizioni Minerva Medica S.p.A.",
number = "6",

}

TY - JOUR

T1 - The endothelial function in cardiac surgery

AU - Ranucci, M.

PY - 2006/6

Y1 - 2006/6

N2 - Cardiac operations with cardiopulmonary bypass exerts many different actions which modify the natural function of endothelial cells. The main determinant is the activation of the coagulation system both through the intrinsic and extrinsic pathways, leading to an overwhelming thrombin formation. To counteract the coagulant effects of thrombin, heparin is used in large doses. As a result, the endothelium is asked to promote all its anticoagulant properties, basically through the AT release from the suface, the tissue factor pathway inhibitor release, and the activation of the protein C - protein S system. At the end of cardiac operations, all these systems are depleted, and low levels of antithrombin, tissue factor pathway inhibitor, protein C are available for further anticoagulant effects. There is the evidence that levels of antithrombin activity below 50% at the end of cardiac operations with cardiopulmonary bypass are associated to bad outcomes in terms of surgical revision rate, thromboembolic events, and neurological events. Exogenous antithrombin administration has a well defined action in limiting thrombin formation during cardiac operations; however, we are still lacking an evidence-based information about the clinical impact of this and others possible preventive strategies based on exogenous administration of antithrombin before or during cardiac operations.

AB - Cardiac operations with cardiopulmonary bypass exerts many different actions which modify the natural function of endothelial cells. The main determinant is the activation of the coagulation system both through the intrinsic and extrinsic pathways, leading to an overwhelming thrombin formation. To counteract the coagulant effects of thrombin, heparin is used in large doses. As a result, the endothelium is asked to promote all its anticoagulant properties, basically through the AT release from the suface, the tissue factor pathway inhibitor release, and the activation of the protein C - protein S system. At the end of cardiac operations, all these systems are depleted, and low levels of antithrombin, tissue factor pathway inhibitor, protein C are available for further anticoagulant effects. There is the evidence that levels of antithrombin activity below 50% at the end of cardiac operations with cardiopulmonary bypass are associated to bad outcomes in terms of surgical revision rate, thromboembolic events, and neurological events. Exogenous antithrombin administration has a well defined action in limiting thrombin formation during cardiac operations; however, we are still lacking an evidence-based information about the clinical impact of this and others possible preventive strategies based on exogenous administration of antithrombin before or during cardiac operations.

KW - Cardiopulmonary bypass

KW - Coagulation

KW - Endothelium, vascular

UR - http://www.scopus.com/inward/record.url?scp=33745278587&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745278587&partnerID=8YFLogxK

M3 - Article

C2 - 16682923

AN - SCOPUS:33745278587

VL - 72

SP - 503

EP - 506

JO - Minerva Anestesiologica

JF - Minerva Anestesiologica

SN - 0375-9393

IS - 6

ER -